Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | FBXW7 S462P |
Gene Variant Detail | |
Relevant Treatment Approaches | mTORC1 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FBXW7 S462P | adult T-cell leukemia/lymphoma | resistant | JQ1 | Preclinical - Cell culture | Actionable | In a preclinical study, adult T cell leukemia cells expressing FBXW7 S462P treated with JQ1 demonstrated resistance in both short term and long term culture, and showed increased phosphorylation of Braf, Mek, and Erk, and increased expression of Stat3 and Myc (PMID: 32907612). | 32907612 | |
FBXW7 S462P | adult T-cell leukemia/lymphoma | resistant | Birabresib | Preclinical - Cell culture | Actionable | In a preclinical study, adult T cell leukemia cells expressing FBXW7 S462P were resistant to treatment with Birabresib (OTX015) in culture (PMID: 32907612). | 32907612 | |
FBXW7 S462P | adult T-cell leukemia/lymphoma | sensitive | JQ1 + PLX8394 | Preclinical - Cell culture | Actionable | In a preclinical study, the combination treatment of JQ1 and PLX8394 resulted in greater decreased proliferation of adult T cell leukemia cells expressing FBXW7 S462P when compared to treatment with JQ1 alone in culture (PMID: 32907612). | 32907612 | |
FBXW7 S462P | adult T-cell leukemia/lymphoma | sensitive | JQ1 + Ulixertinib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination treatment of JQ1 and Ulixertinib (BVD-523) resulted in greater decreased proliferation of adult T cell leukemia cells expressing FBXW7 S462P when compared to treatment with JQ1 alone in culture (PMID: 32907612). | 32907612 |